# OncoSynergy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncosynergy

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.oncosynergy.com
- Total disclosed funding: $20M
- Latest round: Series A (Apr 30, 2018)
- Investors on record: 3

## About

OncoSynergy, Inc. is focused on developing next-generation immunotherapies, specifically targeting high-grade gliomas with its investigational drug OS2966, utilizing advanced delivery methods to overcome therapeutic barriers.OncoSynergy, Inc. was founded in 2011 and is headquartered in South San Francisco, US. The company specializes in immunotherapy solutions, notably for high-grade glioma, and has raised a total of USD 0.20 mn through two deals, with the most recent funding round occurring in May 2019. The firm is led by CEO Anne-Marie Carbonell, who has a background in the biotechnology sector, although details of prior ventures are not provided.OncoSynergy specializes in developing next-generation immunotherapies, with a primary focus on the investigational drug OS2966. This therapeutic antibody is designed to inhibit a cell surface receptor that plays a crucial role in the growth, spread, and treatment resistance of cancer, specifically targeting recurrent and progressive high-grade glioma (HGG). By utilizing convection-enhanced delivery (CED), OS2966 is administered directly into the brain, overcoming the challenges posed by the blood-brain barrier. The company’s approach addresses critical unmet needs in the treatment of HGG, providing a novel therapeutic option for patients requiring surgical resection. OncoSynergy's offerings serve a patient base primarily comprised of individuals diagnosed with HGG, in markets including the United States and potentially expanding to European regions as clinical trials progress.OncoSynergy's revenue model is primarily based on the advancement of its clinical-stage immunotherapy products, notably OS2966. The company engages in strategic partnerships and collaborations with clinical research organizations to facilitate its drug development process. Revenue generation is expected through collaborations with healthcare institutions and pharmaceutical companies aiming to explore the therapeutic potential of its offerings in clinical settings. Transactions are structured around milestone payments and funding for clinical trials, emphasizing collaborative research and potential future licensing agreements. The focus remains on delivering innovative solutions for high-grade glioma patients, positioning OncoSynergy for future revenue opportunities as its products advance through clinical stages.OncoSynergy plans to leverage its recent funding of USD 0.20 mn raised in May 2019 to support the advancement and clinical trials of its investigational drug OS2966. The company aims to introduce new products within its immunotherapy portfolio as clinical data emerges, with specific timelines dependent on regulatory approvals. Additionally, OncoSynergy is looking to expand its market presence in Europe as clinical trials progress, enhancing its reach beyond the United States to address broader patient needs.

## Funding rounds

- Series A, Apr 30, 2018, $20M — Connecticut Innovations, Korea Telecommunications Operations Association, NLabs

## Investors

- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A
- Korea Telecommunications Operations Association — Series A
- NLabs — Series A